What is Aspen Aerogels Inc's earnings per share (EPS)?

Aspen Aerogels Inc (ASPN) reported diluted earnings per share of $-4.73 for fiscal year 2025. This represents a -2882.4% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Aspen Aerogels Inc Financials

ASPN

Source SEC Filings (10-K/10-Q) Updated Mar 23, 2026 Currency USD FYE March

This page shows Aspen Aerogels Inc (ASPN) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 14 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 32/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Aspen Aerogels Inc has an operating margin of -139.5%, meaning the company retains $-140 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is down from 12.0% the prior year.

Growth

Aspen Aerogels Inc's revenue declined 40.1% year-over-year, from $452.7M to $271.1M. This contraction results in a growth score of 0/100.

Leverage

Aspen Aerogels Inc carries a low D/E ratio of 0.28, meaning only $0.28 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 96/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

With a current ratio of 3.90, Aspen Aerogels Inc holds $3.90 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 77/100.

Cash Flow

While Aspen Aerogels Inc generated $32.9M in operating cash flow, capex of $37.4M consumed most of it, leaving -$4.6M in free cash flow. This results in a low score of 21/100, reflecting heavy capital investment rather than weak cash generation.

Returns

Aspen Aerogels Inc generates a -165.4% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is down from 2.2% the prior year.

Piotroski F-Score Neutral

4/9

Aspen Aerogels Inc passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality Mixed

-0.08x

For every $1 of reported earnings, Aspen Aerogels Inc generates $-0.08 in operating cash flow ($32.9M OCF vs -$389.6M net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.

Interest Coverage At Risk

-50.4x

Aspen Aerogels Inc earns $-50.4 in operating income for every $1 of interest expense (-$378.2M vs $7.5M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$271.1M

YoY-40.1%

5Y CAGR+22.0%

10Y CAGR+8.3%

Aspen Aerogels Inc generated $271.1M in revenue in fiscal year 2025. This represents a decrease of 40.1% from the prior year.

EBITDA

-$333.1M

YoY-532.2%

Aspen Aerogels Inc's EBITDA was -$333.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 532.2% from the prior year.

Net Income

-$389.6M

YoY-3012.5%

Aspen Aerogels Inc reported -$389.6M in net income in fiscal year 2025. This represents a decrease of 3012.5% from the prior year.

EPS (Diluted)

$-4.73

YoY-2882.4%

Aspen Aerogels Inc earned $-4.73 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 2882.4% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$4.6M

YoY+88.8%

Aspen Aerogels Inc generated -$4.6M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 88.8% from the prior year.

Cash & Debt

$156.9M

YoY-29.0%

5Y CAGR+56.9%

10Y CAGR+16.9%

Aspen Aerogels Inc held $156.9M in cash against $65.5M in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

83M

YoY+1.0%

5Y CAGR+24.4%

10Y CAGR+13.6%

Aspen Aerogels Inc had 83M shares outstanding in fiscal year 2025. This represents an increase of 1.0% from the prior year.

Margins & Returns

Gross Margin

17.0%

YoY-23.4pp

5Y CAGR+2.4pp

10Y CAGR-3.1pp

Aspen Aerogels Inc's gross margin was 17.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 23.4 percentage points from the prior year.

Operating Margin

-139.5%

YoY-151.6pp

5Y CAGR-118.0pp

10Y CAGR-134.4pp

Aspen Aerogels Inc's operating margin was -139.5% in fiscal year 2025, reflecting core business profitability. This is down 151.6 percentage points from the prior year.

Net Margin

-143.7%

YoY-146.6pp

5Y CAGR-121.9pp

10Y CAGR-138.5pp

Aspen Aerogels Inc's net profit margin was -143.7% in fiscal year 2025, showing the share of revenue converted to profit. This is down 146.6 percentage points from the prior year.

Return on Equity

-165.4%

YoY-167.6pp

5Y CAGR-133.3pp

10Y CAGR-160.2pp

Aspen Aerogels Inc's ROE was -165.4% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 167.6 percentage points from the prior year.

Capital Allocation

R&D Spending

$13.4M

YoY-25.7%

5Y CAGR+9.0%

10Y CAGR+9.8%

Aspen Aerogels Inc invested $13.4M in research and development in fiscal year 2025. This represents a decrease of 25.7% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$37.4M

YoY-56.6%

5Y CAGR+61.4%

10Y CAGR+5.5%

Aspen Aerogels Inc invested $37.4M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 56.6% from the prior year.

ASPN Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$271.1M-40.1%	$452.7M+89.6%	$238.7M+32.4%	$180.4M+48.3%	$121.6M+21.3%	$100.3M
Cost of Revenue	$225.1M-16.6%	$269.8M+48.4%	$181.8M+3.7%	$175.4M+57.0%	$111.7M+30.4%	$85.7M
Gross Profit	$46.0M-74.9%	$182.9M+221.3%	$56.9M+1043.9%	$5.0M-49.9%	$9.9M-31.9%	$14.6M
R&D Expenses	$13.4M-25.7%	$18.1M+10.4%	$16.4M-3.4%	$16.9M+48.0%	$11.4M+31.1%	$8.7M
SG&A Expenses	$55.8M-21.6%	$71.1M+25.3%	$56.8M+47.4%	$38.5M+71.0%	$22.5M+43.6%	$15.7M
Operating Income	-$378.2M-793.6%	$54.5M+210.8%	-$49.2M+37.9%	-$79.2M-95.2%	-$40.6M-88.2%	-$21.6M
Interest Expense	$7.5M+31.6%	$5.7M-34.5%	$8.7M+411.8%	$1.7M+148.6%	-$3.5M-1650.0%	-$200K
Income Tax	$2.4M+39.7%	$1.7M	$0	$0	N/A	N/A
Net Income	-$389.6M-3012.5%	$13.4M+129.2%	-$45.8M+44.6%	-$82.7M-123.0%	-$37.1M-70.1%	-$21.8M
EPS (Diluted)	$-4.73-2882.4%	$0.17+125.8%	$-0.66+68.6%	$-2.10-72.1%	$-1.22-47.0%	$-0.83

Metric	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24
Revenue	$41.3M-43.4%	$73.0M-6.4%	$78.0M-0.9%	$78.7M-36.0%	$123.1M+4.9%	$117.3M-0.4%	$117.8M+24.6%	$94.5M
Cost of Revenue	$64.3M+23.1%	$52.2M-0.9%	$52.7M-5.7%	$55.9M-26.4%	$76.0M+11.2%	$68.3M+3.2%	$66.2M+11.5%	$59.4M
Gross Profit	-$22.9M-210.2%	$20.8M-17.8%	$25.3M+11.0%	$22.8M-51.6%	$47.1M-3.9%	$49.0M-4.9%	$51.6M+46.8%	$35.1M
R&D Expenses	$2.8M+12.1%	$2.5M-34.3%	$3.8M-12.4%	$4.3M-1.6%	$4.4M-4.1%	$4.6M+0.6%	$4.6M+1.7%	$4.5M
SG&A Expenses	$15.4M+13.6%	$13.5M-2.2%	$13.8M+6.2%	$13.0M-30.2%	$18.7M+5.2%	$17.7M+1.4%	$17.5M+1.7%	$17.2M
Operating Income	-$70.4M-2002.3%	-$3.3M+35.1%	-$5.2M+98.3%	-$299.3M-2134.5%	$14.7M-15.4%	$17.4M-12.9%	$20.0M+720.4%	$2.4M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	-$97K-116.3%	$594K-27.6%	$821K-23.7%	$1.1M+714.9%	-$175K-165.5%	$267K-69.2%	$866K+14.6%	$756K
Net Income	-$72.9M-1051.1%	-$6.3M+30.1%	-$9.1M+97.0%	-$301.2M-2751.4%	$11.4M+187.6%	-$13.0M-177.1%	$16.8M+1016.5%	-$1.8M
EPS (Diluted)	N/A	$-0.08+27.3%	$-0.11+97.0%	$-3.67	N/A	$-0.17-181.0%	$0.21+1150.0%	$-0.02

ASPN Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$406.7M-54.6%	$895.1M+27.3%	$703.0M+9.3%	$643.4M+251.7%	$183.0M+87.8%	$97.4M
Current Assets	$242.1M-40.9%	$409.4M+53.7%	$266.3M-28.0%	$369.7M+229.6%	$112.2M+138.0%	$47.1M
Cash & Equivalents	$156.9M-29.0%	$220.9M+58.1%	$139.7M-50.3%	$281.3M+267.5%	$76.6M+364.1%	$16.5M
Inventory	$38.2M-19.6%	$47.6M+21.3%	$39.2M+73.9%	$22.5M+88.0%	$12.0M-8.5%	$13.1M
Accounts Receivable	$35.3M-67.7%	$109.1M+55.9%	$70.0M+22.0%	$57.4M+180.8%	$20.4M+30.1%	$15.7M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$171.2M-39.0%	$280.4M+30.4%	$215.0M+9.7%	$196.0M+259.3%	$54.5M+84.5%	$29.6M
Current Liabilities	$62.0M-43.7%	$110.1M+41.0%	$78.1M-1.1%	$78.9M+116.0%	$36.6M+162.5%	$13.9M
Long-Term Debt	$65.5M-31.1%	$95.0M	N/A	N/A	N/A	$2.1M
Total Equity	$235.5M-61.7%	$614.7M+25.9%	$488.1M+9.1%	$447.4M+248.4%	$128.4M+89.2%	$67.9M
Retained Earnings	-$1.0B-59.0%	-$660.2M+2.0%	-$673.6M-7.3%	-$627.8M-15.2%	-$545.1M-7.3%	-$508.0M

Metric	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24
Total Assets	$406.7M-17.2%	$491.4M-6.4%	$525.1M-5.4%	$555.0M-38.0%	$895.1M+14.4%	$782.6M+4.5%	$748.6M+7.3%	$698.0M
Current Assets	$242.1M-13.2%	$278.9M-10.2%	$310.5M-9.7%	$343.9M-16.0%	$409.4M+33.9%	$305.9M+6.0%	$288.5M+13.1%	$255.1M
Cash & Equivalents	$156.9M+4.1%	$150.7M-10.1%	$167.6M-12.7%	$192.0M-13.1%	$220.9M+94.6%	$113.5M+24.2%	$91.4M-9.9%	$101.5M
Inventory	$38.2M-11.1%	$43.0M-17.4%	$52.1M-8.1%	$56.7M+19.3%	$47.6M+0.3%	$47.4M-10.6%	$53.0M+15.9%	$45.8M
Accounts Receivable	$35.3M-49.0%	$69.1M-9.2%	$76.2M-1.5%	$77.4M-29.1%	$109.1M-5.3%	$115.2M-1.5%	$116.9M+39.2%	$84.0M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$171.2M-7.8%	$185.7M-14.2%	$216.4M-9.9%	$240.1M-14.4%	$280.4M+2.0%	$274.9M+19.1%	$230.8M+11.6%	$206.8M
Current Liabilities	$62.0M-12.3%	$70.7M-9.4%	$78.0M-4.2%	$81.4M-26.0%	$110.1M+5.6%	$104.3M+25.0%	$83.4M+31.2%	$63.6M
Long-Term Debt	$65.5M-6.6%	$70.1M-9.3%	$77.3M-19.0%	$95.4M+0.5%	$95.0M+1.4%	$93.7M	N/A	N/A
Total Equity	$235.5M-23.0%	$305.7M-1.0%	$308.8M-1.9%	$314.8M-48.8%	$614.7M+21.1%	$507.6M-2.0%	$517.8M+5.4%	$491.2M
Retained Earnings	-$1.0B-7.5%	-$976.9M-0.7%	-$970.5M-0.9%	-$961.5M-45.6%	-$660.2M+1.7%	-$671.6M-2.0%	-$658.6M+2.5%	-$675.4M

ASPN Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	$32.9M-27.8%	$45.5M+206.9%	-$42.6M+54.9%	-$94.4M-406.8%	-$18.6M-87.7%	-$9.9M
Capital Expenditures	$37.4M-56.6%	$86.3M-50.8%	$175.5M-1.4%	$178.0M+1191.7%	$13.8M+303.3%	$3.4M
Free Cash Flow	-$4.6M+88.8%	-$40.7M+81.3%	-$218.1M+19.9%	-$272.4M-740.5%	-$32.4M-142.9%	-$13.3M
Investing Cash Flow	-$37.4M+56.6%	-$86.3M+50.8%	-$175.5M+1.4%	-$178.0M-1191.7%	-$13.8M-303.3%	-$3.4M
Financing Cash Flow	-$58.1M-147.6%	$122.0M+61.7%	$75.5M-84.2%	$478.4M+417.3%	$92.5M+252.9%	$26.2M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24
Operating Cash Flow	$16.1M+7.3%	$15.0M+482.6%	-$3.9M-169.8%	$5.6M-84.2%	$35.7M+71.8%	$20.8M+203.5%	$6.8M+138.6%	-$17.7M
Capital Expenditures	$2.5M-72.9%	$9.1M-29.4%	$12.9M-0.9%	$13.0M-11.9%	$14.8M-29.2%	$20.8M-16.1%	$24.8M-4.0%	$25.9M
Free Cash Flow	$13.7M+130.4%	$5.9M+135.3%	-$16.8M-128.3%	-$7.4M-135.2%	$20.9M+41966.0%	-$50K+99.7%	-$18.0M+58.8%	-$43.6M
Investing Cash Flow	-$2.5M+72.9%	-$9.1M+29.4%	-$12.9M+0.9%	-$13.0M+11.9%	-$14.8M+29.2%	-$20.8M+16.1%	-$24.8M+4.0%	-$25.9M
Financing Cash Flow	-$7.5M+65.0%	-$21.5M-183.9%	-$7.6M+64.7%	-$21.5M-124.8%	$86.5M+290.2%	$22.2M+172.2%	$8.1M+54.8%	$5.3M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

ASPN Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	17.0%-23.4pp	40.4%+16.6pp	23.8%+21.1pp	2.8%-5.4pp	8.2%-6.4pp	14.5%
Operating Margin	-139.5%-151.6pp	12.0%+32.7pp	-20.6%+23.3pp	-43.9%-10.6pp	-33.4%-11.9pp	-21.5%
Net Margin	-143.7%-146.6pp	2.9%+22.1pp	-19.2%+26.7pp	-45.9%-15.4pp	-30.5%-8.8pp	-21.8%
Return on Equity	-165.4%-167.6pp	2.2%+11.6pp	-9.4%+9.1pp	-18.5%+10.4pp	-28.9%+3.3pp	-32.1%
Return on Assets	-95.8%-97.3pp	1.5%+8.0pp	-6.5%+6.3pp	-12.9%+7.4pp	-20.3%+2.1pp	-22.4%
Current Ratio	3.90+0.2	3.72+0.3	3.41-1.3	4.68+1.6	3.07-0.3	3.38
Debt-to-Equity	0.28+0.1	0.15-0.3	0.440.0	0.44+0.0	0.42+0.4	0.03
FCF Margin	-1.7%+7.3pp	-9.0%+82.4pp	-91.3%+59.7pp	-151.0%-124.4pp	-26.6%-13.3pp	-13.3%

Metric	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24
Gross Margin	-55.5%-84.0pp	28.5%-4.0pp	32.5%+3.5pp	29.0%-9.3pp	38.3%-3.5pp	41.8%-2.0pp	43.8%+6.6pp	37.2%
Operating Margin	-170.3%-165.7pp	-4.6%+2.0pp	-6.6%+373.6pp	-380.3%-392.2pp	11.9%-2.9pp	14.8%-2.1pp	17.0%+14.4pp	2.6%
Net Margin	-176.4%-167.7pp	-8.7%+2.9pp	-11.6%+371.1pp	-382.7%-391.9pp	9.2%+20.3pp	-11.1%-25.3pp	14.3%+16.2pp	-1.9%
Return on Equity	-31.0%-28.9pp	-2.1%+0.9pp	-2.9%+92.8pp	-95.7%-97.5pp	1.8%+4.4pp	-2.5%-5.8pp	3.3%+3.6pp	-0.4%
Return on Assets	-17.9%-16.6pp	-1.3%+0.4pp	-1.7%+52.6pp	-54.3%-55.5pp	1.3%+2.9pp	-1.7%-3.9pp	2.3%+2.5pp	-0.3%
Current Ratio	3.90-0.0	3.94-0.0	3.98-0.2	4.22+0.5	3.72+0.8	2.93-0.5	3.46-0.6	4.01
Debt-to-Equity	0.28+0.0	0.23-0.0	0.25-0.1	0.30+0.1	0.15-0.0	0.18-0.3	0.45+0.0	0.42
FCF Margin	33.1%+24.9pp	8.1%+29.7pp	-21.6%-12.2pp	-9.4%-26.4pp	17.0%+17.1pp	-0.0%+15.2pp	-15.3%+30.9pp	-46.2%

Similar Companies

Jeld Wen Holding JELD

$94.9M

Quanex Build NX

$802.0M

Latham Group, Inc. SWIM

$607.0M

Apogee Entr APOG

$717.4M

Janus International Group Inc JBI

$683.2M

Frequently Asked Questions

What is Aspen Aerogels Inc's annual revenue?

Aspen Aerogels Inc (ASPN) reported $271.1M in total revenue for fiscal year 2025. This represents a -40.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Aspen Aerogels Inc's revenue growing?

Aspen Aerogels Inc (ASPN) revenue declined by 40.1% year-over-year, from $452.7M to $271.1M in fiscal year 2025.

Is Aspen Aerogels Inc profitable?

No, Aspen Aerogels Inc (ASPN) reported a net income of -$389.6M in fiscal year 2025, with a net profit margin of -143.7%.

What is Aspen Aerogels Inc's EBITDA?

Aspen Aerogels Inc (ASPN) had EBITDA of -$333.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Aspen Aerogels Inc have?

As of fiscal year 2025, Aspen Aerogels Inc (ASPN) had $156.9M in cash and equivalents against $65.5M in long-term debt.

What is Aspen Aerogels Inc's gross margin?

Aspen Aerogels Inc (ASPN) had a gross margin of 17.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Aspen Aerogels Inc's operating margin?

Aspen Aerogels Inc (ASPN) had an operating margin of -139.5% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Aspen Aerogels Inc's net profit margin?

Aspen Aerogels Inc (ASPN) had a net profit margin of -143.7% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Aspen Aerogels Inc's return on equity (ROE)?

Aspen Aerogels Inc (ASPN) has a return on equity of -165.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Aspen Aerogels Inc's free cash flow?

Aspen Aerogels Inc (ASPN) generated -$4.6M in free cash flow during fiscal year 2025. This represents a 88.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Aspen Aerogels Inc's operating cash flow?

Aspen Aerogels Inc (ASPN) generated $32.9M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Aspen Aerogels Inc's total assets?

Aspen Aerogels Inc (ASPN) had $406.7M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Aspen Aerogels Inc's capital expenditures?

Aspen Aerogels Inc (ASPN) invested $37.4M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Aspen Aerogels Inc spend on research and development?

Aspen Aerogels Inc (ASPN) invested $13.4M in research and development during fiscal year 2025.

How many shares does Aspen Aerogels Inc have outstanding?

Aspen Aerogels Inc (ASPN) had 83M shares outstanding as of fiscal year 2025.

What is Aspen Aerogels Inc's current ratio?

Aspen Aerogels Inc (ASPN) had a current ratio of 3.90 as of fiscal year 2025, which is generally considered healthy.

What is Aspen Aerogels Inc's debt-to-equity ratio?

Aspen Aerogels Inc (ASPN) had a debt-to-equity ratio of 0.28 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Aspen Aerogels Inc's return on assets (ROA)?

Aspen Aerogels Inc (ASPN) had a return on assets of -95.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Aspen Aerogels Inc's Piotroski F-Score?

Aspen Aerogels Inc (ASPN) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Aspen Aerogels Inc's earnings high quality?

Aspen Aerogels Inc (ASPN) has an earnings quality ratio of -0.08x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Aspen Aerogels Inc cover its interest payments?

Aspen Aerogels Inc (ASPN) has an interest coverage ratio of -50.4x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Aspen Aerogels Inc?

Aspen Aerogels Inc (ASPN) scores 32 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.